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Phosphodiesterase-4 Activity
A Critical Modulator of Atrial
Contractility and Arrhythmogenesis*
David R. Van Wagoner, PHD,†
Bruce D. Lindsay, MD‡
Cleveland, Ohio
Atrial excitation-contraction coupling (ECC) and pace-
maker activity are both dependent on intracellular calcium
(Ca2) cycling, and alterations in Ca2 cycling are strongly
mplicated in the pathophysiology of atrial fibrillation (AF).
epolarization of cardiac myocytes promotes Ca2 influx
via L-type calcium channels (LTCCs), which then releases
a larger quantity of Ca2 from intracellular stores. For
ECC, elevated Ca2 interacts with troponin C, promoting
cross bridge interaction and myocyte contraction. Relax-
ation during diastole requires intracellular Ca2 levels to
eturn to baseline levels, either via reuptake of Ca2 into the
arcoplasmic reticulum or extrusion from the cell by the
odium calcium exchanger. In pacemaking cells, Ca2 influx
via the LTCC underlies the upstroke of the action potential;
Ca2 (and sodium) influx via HCN (hyperpolarization-
activated cyclic nucleotide-gated) channels regulates the rate
of diastolic depolarization.
See page 2182
Given the critical role of Ca2 cycling in atrial contractile
nd pacemaker functions, it is not surprising that these
rocesses are highly regulated. Sympathetic nerve activity
ncreases heart rate and cardiac output by increasing Ca2
influx and cycling in both the sinoatrial (SA) node and in
the working atrial myocardium. Norepinephrine released
from cardiac nerve terminals activates beta-adrenergic re-
ceptors (beta-ARs) in the heart. Beta-AR activation in-
creases production of cyclic adenosine monophosphate
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tion of cAMP, by inhibiting the activity of adenylate
cyclase. Elevated cAMP levels increase protein kinase A
(PKA) activity, promoting the phosphorylation of the
LTCC, ryanodine receptor, HCN channels, troponin I, and
phospholamban. Thus, during sympathetic stimulation,
Ca2 influx is enhanced, heart rate is increased, the Ca2
transient is larger, contractile activity is increased, and
reuptake of Ca2 into the sarcoplasmic reticulum is en-
hanced. Enhanced Ca2 cycling comes at the cost of
ncreased demand for adenosine triphosphate, oxygen, and
etabolic substrates.
When sympathetic activation subsides, intracellular phos-
hodiesterases (PDEs) degrade cAMP, reducing PKA ac-
ivity. Atrial PDEs are important modulators of heart rate,
ardiac contractility, and energy demand. Too little PDE
ctivity can lead to prolonged tachycardia, increased con-
ractile activity, and enhanced pacemaker activity—both in
he sinoatrial node and in secondary pacemakers (such as
hose in the pulmonary vein region or around the mitral
alve). This can promote Ca2 overload, initiate myocyte
poptosis, and act as a trigger for AF. Too much PDE
ctivity can diminish the ability of the heart to respond to
tress and reduce cardiac contractile activity. We and others
ave shown that in persistent AF, perhaps as an adaptation
o rate-induced intracellular Ca2 overload, Ca2 influx
through the LTCC is reduced (1), leading to impaired
contractility, and increasing risk of thrombus formation and
stroke (2). PDEs thus have a significant impact on atrial
contractile and electrical activity, and can affect risk of AF
and stroke.
PDE isoforms vary in substrate specificity (degrading
cAMP, cyclic guanosine monophosphate, or both). They
have different kinetics and affinity for cyclic nucleotides.
The intracellular localization and regional distribution of
PDEs vary. PDE3 is the most abundant PDE expressed in
human atria. Previous pharmacological studies character-
ized, in detail, the impact of PDE3 inhibitors on the
adrenergic responses of human atrial myocyte contractility
and calcium currents (3–5). Although PDE3 is the most
abundant PDE in the human atrium, it is not the only
isoform.
In this issue of the Journal, Molina et al. (6) carefully
document the presence, function, and significance of PDE4
(A, B, and D) isoforms in human atrial myocytes. Using a
combination of classical and state-of-the-art techniques, the
investigators synthesize a novel and coherent understanding
of the physiological significance of PDE4 in human atria.
The authors show that although PDE4 constitutes only
about 15% of total PDE activity, PDE4 isoforms have a very
significant impact on cAMP levels and on the Ca2 channel
esponse to beta-ARs agonists. They demonstrate that
DE4 A, B, and D isoforms are expressed in human atrial
yocytes, and report that PDE4D is the most abundant. Insolated human atrial myocytes, pharmacological inhibition
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PDE4/Atrial Arrhythmogenesis June 12, 2012:2191–2of PDE4 activity during exposure to beta-ARs was associ-
ated with a prolongation of the increase in cAMP levels.
PDE4 inhibition increased LTCC density and increased
the rate of spontaneous sarcoplasmic reticulum calcium
release events. Similarly, in intact human atrial trabeculae,
inhibition of PDE4 activity increased the contractile re-
sponse to beta-ARs and increased arrhythmic contractile
activity.
Interestingly, the investigators were able to assess PDE
activity in right atrial tissues from 18 patients in sinus
rhythm and 7 patients with permanent AF. Total PDE
activity was25% lower in patients with AF compared with
those in sinus rhythm (p  0.059). The difference was even
greater with respect to PDE4 activity, which was reduced by
48% in AF patients versus those in sinus rhythm (p 
0.029). The investigators noted (not surprisingly) that the
AF patients were older than those in sinus rhythm. Regres-
sion analysis confirmed that PDE4 activity was negatively
associated with age. In an age-matched comparison, the
difference between patients with AF versus those in sinus
rhythm was smaller, but still approached statistical signifi-
cance (p  0.057). It thus seems likely that loss of PDE4
activity contributes to AF risk, and that the presence of AF
is associated with a further reduction in PDE4 activity.
Although a number of pro-arrhythmic pathways (sympa-
thetic tone, hypertension, fibrosis, and so on.) also increase
in prevalence with age, the results of Molina et al. (6) are
intriguing.
These studies suggest that, by minimizing Ca2 influx
and spontaneous release events, PDE4 decreases the fre-
quency of Ca2 release mediated ectopic events and protects
gainst arrhythmic activity. The studies in this report
ocused on right atrial appendage tissue specimens. As
uch of the current clinical focus on AF treatment centers
n isolation of ectopic activity originating in the pulmonary
ein region of the left atrium, it would be of interest in
uture studies to evaluate the regional abundance and
istribution of PDE isoforms in the left and right atrial
odies, appendages, SA and atrioventricular nodes, and in
he pulmonary vein region.
A primary concern for AF patients is the risk of cardio-
mbolic stroke; AF increases risk of stroke 5- to 7-fold (7).
olina et al. (6) note that PDE4D has been linked to stroke
isk in genome-wide association studies with stroke end-
oints (8,9), but point out that these studies have not yet
onsidered the possibility that atrial PDE4D may underlie
his relationship. On the basis of the results presented, this
eems to be a logical and important hypothesis. In genome
ide association studies of AF cohorts (10,11), it will be
ossible to assess the role of PDE4D as a candidate gene
ssociated with stroke risk. In such a study, if the number of
trokes reported is sufficient, it should be straightforward to hvaluate the hypothesis that atrial PDE4D activity is caus-
lly related with stroke as a result of AF.
AF is the most common arrhythmia, and currently
vailable antiarrhythmic treatments based on ion channel
lockade have limited efficacy. Considerable recent effort
as focused on the development of novel anticoagulants that
elp to reduce stroke risk in AF. Although these agents are
elcomed and are likely to be exceptionally valuable, the
tudy of Molina et al. (6) suggests the intriguing hypothesis
hat novel agents that selectively enhance PDE4D activity
ight simultaneously prevent atrial contractile dysfunction,
imit atrial energy demands associated with Ca2 cycling,
help to prevent AF, and decrease stroke risk. Efforts to test
this hypothesis would represent a significant step toward
more effective management of AF.
Reprint requests and correspondence: Dr. David R. Van Wag-
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